New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Orphan Drugs Industry" - https://www.reportlinker.com/p06051495/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year
Global Orphan Drugs Market to Reach $545.4 Billion by 2027
Amid the COVID-19 crisis, the global market for Orphan Drugs estimated at US$201.9 Billion in the year 2020, is projected to reach a revised size of US$545.4 Billion by 2027, growing at aCAGR of 15.3% over the period 2020-2027. Biologics, one of the segments analyzed in the report, is projected to record 15.8% CAGR and reach US$344.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Biologics segment is readjusted to a revised 14.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $59.1 Billion, While China is Forecast to Grow at 14.6% CAGR
The Orphan Drugs market in the U.S. is estimated at US$59.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$94.7 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 12.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.
Select Competitors (Total 18 Featured) -
AbbVie Inc.
Actelion Pharmaceuticals Ltd.
Alexion Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc.
Bayer AG
Biogen Inc.
BioMarin Pharmaceutical Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp.
CEL-SCI Corporation
Concordia International Corp.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genzyme Corp.,
Johnson & Johnson
Merck & Co. Inc.
Merck Serono SA
Novartis AG
Pfizer Inc.
Recordati S.p.A.
Sanofi SA
Shire Plc.
Vertex Pharmaceuticals
Read the full report: https://www.reportlinker.com/p06051495/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Prelude
Recent Market Activity
Increasing Adoption of Orphan Drugs by Manufacturers
The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
Major Orphan Drugs Legislations Worldwide
Orphan Drugs Market on a Rapid Growth Trajectory
Select Major Organizations Dealing with Rare Diseases in the
US, Canada, and EU
Incentives for Orphan Drug Designation Products in the US, EU,
and Japan
Market Challenges
Obstacles for Conducting Orphan Drug Research
Competition
Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
Important Orphan Drugs in Pipeline
Orphan Drugs - Global Key Competitors Percentage Market Share
in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AbbVie, Inc. (USA)
Actelion Pharmaceuticals Ltd. (Switzerland)
Alexion Pharmaceuticals, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Biogen Inc. (USA)
BioMarin Pharmaceutical Inc. (USA)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Celgene Corp. (USA)
CEL-SCI Corporation (USA)
Concordia International Corp. (Canada)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
Merck Serono International S.A. (Germany)
Merck Serono International S.A. (Germany)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Recordati S.p.A. (Italy)
Orphan Europe (France)
Shire Plc. (Ireland)
Sanofi SA (France)
Genzyme Corp. (USA)
Vertex Pharmaceuticals (USA)
3. MARKET TRENDS & DRIVERS
Regulatory Incentives - A Push in the Right Direction
Growing Unmet Medical Needs - Fulfilling the Gap
Rising Incidence of Rare Forms of Cancer - Opportunities Galore
Select Orphan Drugs for Cancer
Rise in Incidence of Renal Cell Carcinoma
Unmet Needs in AML
Aging Population Offers Growth Potential
Pre-Symptomatic Screening to Expand Market Base
Asia?s Rising Awareness and Growing Population to Drive Sales
Drug Repurposing Provides Therapies for Rare Diseases
The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
Interest of Major Pharmaceutical Firms Signal a Shift in
Commercial Dynamics
Mergers and Acquisitions Drive Market Growth
Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
Growing Scrutiny over Skyrocketing Prices
Orphan Drugs with High Prices: 2016
Medical Advancements Foster Growth
Full Reimbursements Critical for Spurring Uptake of High-Priced
Orphan Drugs
Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
Strong Market Potential for Ultra-Orphan Drugs for Amyloid
Light-chain Amyloidosis
Increasing Patient Engagement - The PAG Trend
Gene Therapy and Bioprocessing Preferred over Chronic Therapies
Companies Developing Gene Therapies
International Collaboration - The Way Forward
CNS Therapeutics to Gain Focus in the Orphan Drugs Market
Manufacturers Target Orphan Indications to Curtail Competition
in Broader Indications
Manufacturers Use Orphan Disease to Target Larger Therapeutic
Indications
Treating Autism - The Next Big Thing?
Sequencing Technology - The New Research Tool for Orphan Drugs
Innovations in Biotechnology - A Boon for Orphan Drug Research
Aging Gene Linked to Myeloma
Antibody with Potential to Treat Multiple Myeloma
Potential Treatment for Cystic Fibrosis Patients Infected with
Mycobacterium abscessus
Genetic Variants to Improve Treatment of Non-small Cell Lung
Cancer
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Orphan Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 2: World Historic Review for Orphan Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Orphan Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for
Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 5: World Historic Review for Biologics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Biologics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for
Non-Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 8: World Historic Review for Non-Biologics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Non-Biologics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 11: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Hematology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 14: World Historic Review for Hematology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Hematology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 16: World Recent Past, Current & Future Analysis for
Neurology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 17: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for
Cardiovascular by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 20: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 21: World 15-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 22: World Recent Past, Current & Future Analysis for
Other Disease Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 23: World Historic Review for Other Disease Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Other Disease Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 25: World Recent Past, Current & Future Analysis for
Endocrinology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 26: World Historic Review for Endocrinology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Endocrinology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 28: World Recent Past, Current & Future Analysis for
Respiratory by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 29: World Historic Review for Respiratory by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 30: World 15-Year Perspective for Respiratory by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 31: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 32: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 34: World Orphan Drugs Market Analysis of Annual Sales in
US$ Million for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2022 (E)
Table 35: USA Recent Past, Current & Future Analysis for Orphan
Drugs by Drug Type - Biologics and Non-Biologics - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 36: USA Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 37: USA 15-Year Perspective for Orphan Drugs by Drug Type -
Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 38: USA Recent Past, Current & Future Analysis for Orphan
Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 39: USA Historic Review for Orphan Drugs by Disease Type -
Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 40: USA 15-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
CANADA
Table 41: Canada Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 42: Canada Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 43: Canada 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 44: Canada Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 45: Canada Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 46: Canada 15-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
JAPAN
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2022 (E)
Table 47: Japan Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 48: Japan Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 49: Japan 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 50: Japan Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 51: Japan Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 52: Japan 15-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
CHINA
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2022 (E)
Table 53: China Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 54: China Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 55: China 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 56: China Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 57: China Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 58: China 15-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
EUROPE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2022 (E)
Table 59: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 60: Europe Historic Review for Orphan Drugs by Geographic
Region - France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 61: Europe 15-Year Perspective for Orphan Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2021 & 2027
Table 62: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 63: Europe Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 64: Europe 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 65: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 66: Europe Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 67: Europe 15-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
FRANCE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2022 (E)
Table 68: France Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 69: France Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 70: France 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 71: France Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 72: France Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 73: France 15-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
GERMANY
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2022 (E)
Table 74: Germany Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 75: Germany Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 76: Germany 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 77: Germany Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 78: Germany Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 79: Germany 15-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
ITALY
Table 80: Italy Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 81: Italy Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 82: Italy 15-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 83: Italy Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 84: Italy Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 85: Italy 15-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
UNITED KINGDOM
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2022 (E)
Table 86: UK Recent Past, Current & Future Analysis for Orphan
Drugs by Drug Type - Biologics and Non-Biologics - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 87: UK Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 88: UK 15-Year Perspective for Orphan Drugs by Drug Type -
Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2012, 2021 & 2027
Table 89: UK Recent Past, Current & Future Analysis for Orphan
Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 90: UK Historic Review for Orphan Drugs by Disease Type -
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 91: UK 15-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 93: Rest of Europe Historic Review for Orphan Drugs by
Drug Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 94: Rest of Europe 15-Year Perspective for Orphan Drugs
by Drug Type - Percentage Breakdown of Value Sales for
Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR
Table 96: Rest of Europe Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 97: Rest of Europe 15-Year Perspective for Orphan Drugs
by Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
ASIA-PACIFIC
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Asia-Pacific for 2022 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 99: Asia-Pacific Historic Review for Orphan Drugs by Drug
Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 100: Asia-Pacific 15-Year Perspective for Orphan Drugs by
Drug Type - Percentage Breakdown of Value Sales for Biologics
and Non-Biologics for the Years 2012, 2021 & 2027
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR
Table 102: Asia-Pacific Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 103: Asia-Pacific 15-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
REST OF WORLD
Table 104: Rest of World Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 105: Rest of World Historic Review for Orphan Drugs by
Drug Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 106: Rest of World 15-Year Perspective for Orphan Drugs
by Drug Type - Percentage Breakdown of Value Sales for
Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Table 107: Rest of World Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR
Table 108: Rest of World Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 109: Rest of World 15-Year Perspective for Orphan Drugs
by Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2012, 2021 & 2027
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06051495/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
